Confusion reigns about drug procurement in MOH, with issues like delays in procuring medicines, risking shortages; choosing generics at 100% to 200% higher prices than off-patent innovators; “opaque” tenders and insufficient support for the local industry.| CodeBlue
The Ministry of Health will begin using real-world evidence like treatment outcomes from hospitals to inform drug listings in the MOH formulary, moving away from relying on clinical trial data alone in a shift towards value-based care and patient outcomes.| CodeBlue